Tandem Diabetes Care (TNDM)
Market Price (7/8/2026): $15.445 | Market Cap: $1.1 BilSector: Health Care | Industry: Health Care Equipment
Tandem Diabetes Care (TNDM)
Market Price (7/8/2026): $15.445Market Cap: $1.1 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -30% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Diabetes Management, Remote Patient Monitoring, Show more. | Weak multi-year price returns2Y Excs Rtn is -98%, 3Y Excs Rtn is -110% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -64 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.2% Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 54x Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3.8% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13% Key risksTNDM key risks include [1] eroding U.S. Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -30% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Diabetes Management, Remote Patient Monitoring, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -98%, 3Y Excs Rtn is -110% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -64 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.2% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 54x |
| Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3.8% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13% |
| Key risksTNDM key risks include [1] eroding U.S. Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/1/2026
Tandem Diabetes Care (TNDM) stock has lost about 20% since 3/31/2026 because of the following key factors:
1. Strategic Shift Impacting Near-Term Revenue Visibility. Tandem Diabetes Care is undergoing a significant transition to a pharmacy-based, "pay-as-you-go" reimbursement model for its U.S. business, a strategic move intended for long-term growth. This shift, however, introduces complexities in near-term revenue recognition patterns, leading to 2026 financial guidance being below analyst consensus expectations and contributing to investor uncertainty. While Q1 2026 saw pharmacy sales account for 6% of U.S. sales, the different revenue timing associated with this model can reduce immediate sales recognition.
2. Emerging Competitive Pressure from GLP-1 Therapies. A broader industry trend impacting the medical device sector, particularly diabetes management companies, is the increasing adoption of GLP-1 therapies. These therapies are "shifting patient behavior and reshaping care pathways" for diabetes, introducing a significant competitive overhang and uncertainty regarding the future demand for insulin pumps. This trend may temper investor optimism for Tandem's long-term growth prospects.
Show more
Tandem Diabetes Care (TNDM) stock has lost about 20% since 3/31/2026 because of the following key factors:
1. Strategic Shift Impacting Near-Term Revenue Visibility. Tandem Diabetes Care is undergoing a significant transition to a pharmacy-based, "pay-as-you-go" reimbursement model for its U.S. business, a strategic move intended for long-term growth. This shift, however, introduces complexities in near-term revenue recognition patterns, leading to 2026 financial guidance being below analyst consensus expectations and contributing to investor uncertainty. While Q1 2026 saw pharmacy sales account for 6% of U.S. sales, the different revenue timing associated with this model can reduce immediate sales recognition.
2. Emerging Competitive Pressure from GLP-1 Therapies. A broader industry trend impacting the medical device sector, particularly diabetes management companies, is the increasing adoption of GLP-1 therapies. These therapies are "shifting patient behavior and reshaping care pathways" for diabetes, introducing a significant competitive overhang and uncertainty regarding the future demand for insulin pumps. This trend may temper investor optimism for Tandem's long-term growth prospects.
Show more
Updated on 7/1/2026
Tandem Diabetes Care (TNDM) stock has lost about 20% since 3/31/2026 because of the following key factors:
1. Strategic Shift Impacting Near-Term Revenue Visibility. Tandem Diabetes Care is undergoing a significant transition to a pharmacy-based, "pay-as-you-go" reimbursement model for its U.S. business, a strategic move intended for long-term growth. This shift, however, introduces complexities in near-term revenue recognition patterns, leading to 2026 financial guidance being below analyst consensus expectations and contributing to investor uncertainty. While Q1 2026 saw pharmacy sales account for 6% of U.S. sales, the different revenue timing associated with this model can reduce immediate sales recognition.
2. Emerging Competitive Pressure from GLP-1 Therapies. A broader industry trend impacting the medical device sector, particularly diabetes management companies, is the increasing adoption of GLP-1 therapies. These therapies are "shifting patient behavior and reshaping care pathways" for diabetes, introducing a significant competitive overhang and uncertainty regarding the future demand for insulin pumps. This trend may temper investor optimism for Tandem's long-term growth prospects.
3. Lingering Profitability Concerns Despite Q1 2026 Beat. Although Tandem Diabetes Care reported better-than-expected Q1 2026 earnings on May 7, 2026, with an EPS of -$0.30 (beating estimates of -$0.46) and revenue of $247.22 million (above expectations of $240.41 million), and achieved its first positive adjusted EBITDA of $2.7 million since 2022, the company still faces a "lengthy path" to sustained operational profitability. The reported trailing twelve-month net loss of -$204.71 million indicates ongoing challenges in consistently generating profit, contributing to investor caution despite quarterly improvements.
4. Mixed Analyst Sentiment and Valuation Scrutiny. While the consensus analyst rating for TNDM is generally a "Moderate Buy" or "Hold" with an average price target ranging from approximately $26.61 to $30.84, representing significant upside from current levels, there have been divergent views. For instance, Deutsche Bank initiated coverage in June 2026 with a "Hold" rating and a $15.50 price target, notably below the consensus. This mixed sentiment, coupled with a "Possible Value Trap" warning from one analysis highlighting the stock as potentially undervalued but also noting high historical P/E volatility, suggests lingering valuation concerns and uncertainty among investors.
Show less
Tandem Diabetes Care (TNDM) stock has lost about 20% since 3/31/2026 because of the following key factors:
1. Strategic Shift Impacting Near-Term Revenue Visibility. Tandem Diabetes Care is undergoing a significant transition to a pharmacy-based, "pay-as-you-go" reimbursement model for its U.S. business, a strategic move intended for long-term growth. This shift, however, introduces complexities in near-term revenue recognition patterns, leading to 2026 financial guidance being below analyst consensus expectations and contributing to investor uncertainty. While Q1 2026 saw pharmacy sales account for 6% of U.S. sales, the different revenue timing associated with this model can reduce immediate sales recognition.
2. Emerging Competitive Pressure from GLP-1 Therapies. A broader industry trend impacting the medical device sector, particularly diabetes management companies, is the increasing adoption of GLP-1 therapies. These therapies are "shifting patient behavior and reshaping care pathways" for diabetes, introducing a significant competitive overhang and uncertainty regarding the future demand for insulin pumps. This trend may temper investor optimism for Tandem's long-term growth prospects.
3. Lingering Profitability Concerns Despite Q1 2026 Beat. Although Tandem Diabetes Care reported better-than-expected Q1 2026 earnings on May 7, 2026, with an EPS of -$0.30 (beating estimates of -$0.46) and revenue of $247.22 million (above expectations of $240.41 million), and achieved its first positive adjusted EBITDA of $2.7 million since 2022, the company still faces a "lengthy path" to sustained operational profitability. The reported trailing twelve-month net loss of -$204.71 million indicates ongoing challenges in consistently generating profit, contributing to investor caution despite quarterly improvements.
4. Mixed Analyst Sentiment and Valuation Scrutiny. While the consensus analyst rating for TNDM is generally a "Moderate Buy" or "Hold" with an average price target ranging from approximately $26.61 to $30.84, representing significant upside from current levels, there have been divergent views. For instance, Deutsche Bank initiated coverage in June 2026 with a "Hold" rating and a $15.50 price target, notably below the consensus. This mixed sentiment, coupled with a "Possible Value Trap" warning from one analysis highlighting the stock as potentially undervalued but also noting high historical P/E volatility, suggests lingering valuation concerns and uncertainty among investors.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -19.5% change in TNDM stock from 3/31/2026 to 7/7/2026 was primarily driven by a -20.1% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 7072026 | Change |
|---|---|---|---|
| Stock Price ($) | 19.17 | 15.43 | -19.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,015 | 1,028 | 1.3% |
| P/S Multiple | 1.3 | 1.0 | -20.1% |
| Shares Outstanding (Mil) | 68 | 68 | -0.6% |
| Cumulative Contribution | -19.5% |
Market Drivers
3/31/2026 to 7/7/2026| Return | Correlation | |
|---|---|---|
| TNDM | -19.5% | |
| Market (SPY) | 15.0% | 22.4% |
| Sector (XLV) | 12.2% | 36.6% |
Fundamental Drivers
The -29.8% change in TNDM stock from 12/31/2025 to 7/7/2026 was primarily driven by a -30.4% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 7072026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.98 | 15.43 | -29.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,007 | 1,028 | 2.0% |
| P/S Multiple | 1.5 | 1.0 | -30.4% |
| Shares Outstanding (Mil) | 68 | 68 | -1.1% |
| Cumulative Contribution | -29.8% |
Market Drivers
12/31/2025 to 7/7/2026| Return | Correlation | |
|---|---|---|
| TNDM | -29.8% | |
| Market (SPY) | 9.9% | 20.7% |
| Sector (XLV) | 6.7% | 25.4% |
Fundamental Drivers
The -17.2% change in TNDM stock from 6/30/2025 to 7/7/2026 was primarily driven by a -18.4% change in the company's P/S Multiple.| (LTM values as of) | 6302025 | 7072026 | Change |
|---|---|---|---|
| Stock Price ($) | 18.64 | 15.43 | -17.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 983 | 1,028 | 4.5% |
| P/S Multiple | 1.3 | 1.0 | -18.4% |
| Shares Outstanding (Mil) | 66 | 68 | -2.9% |
| Cumulative Contribution | -17.2% |
Market Drivers
6/30/2025 to 7/7/2026| Return | Correlation | |
|---|---|---|
| TNDM | -17.2% | |
| Market (SPY) | 22.0% | 20.1% |
| Sector (XLV) | 23.6% | 31.4% |
Fundamental Drivers
The -37.1% change in TNDM stock from 6/30/2023 to 7/7/2026 was primarily driven by a -48.5% change in the company's P/S Multiple.| (LTM values as of) | 6302023 | 7072026 | Change |
|---|---|---|---|
| Stock Price ($) | 24.54 | 15.43 | -37.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 795 | 1,028 | 29.3% |
| P/S Multiple | 2.0 | 1.0 | -48.5% |
| Shares Outstanding (Mil) | 65 | 68 | -5.6% |
| Cumulative Contribution | -37.1% |
Market Drivers
6/30/2023 to 7/7/2026| Return | Correlation | |
|---|---|---|
| TNDM | -37.1% | |
| Market (SPY) | 74.6% | 26.1% |
| Sector (XLV) | 29.7% | 25.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TNDM Return | 57% | -70% | -34% | 22% | -39% | -30% | -84% |
| Peers Return | 27% | -3% | 11% | 4% | 14% | -12% | 45% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| TNDM Win Rate | 67% | 42% | 33% | 50% | 42% | 43% | |
| Peers Win Rate | 57% | 52% | 47% | 52% | 55% | 49% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 57% | |
Max Drawdowns [4] | |||||||
| TNDM Max Drawdown | -26% | -76% | -69% | -49% | -73% | -55% | |
| Peers Max Drawdown | -22% | -32% | -33% | -27% | -24% | -32% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: PODD, MDT, DXCM, ABT, LLY. See TNDM Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/7/2026 (YTD)
How Low Can It Go
| Event | TNDM | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -20.5% | -7.8% |
| % Gain to Breakeven | 25.8% | 8.5% |
| Time to Breakeven | 15 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -57.4% | -9.5% |
| % Gain to Breakeven | 134.5% | 10.5% |
| Time to Breakeven | 137 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -42.5% | -6.7% |
| % Gain to Breakeven | 74.0% | 7.1% |
| Time to Breakeven | 302 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -47.4% | -33.7% |
| % Gain to Breakeven | 90.1% | 50.9% |
| Time to Breakeven | 54 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -20.6% | -19.2% |
| % Gain to Breakeven | 25.9% | 23.8% |
| Time to Breakeven | 9 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -90.1% | -3.7% |
| % Gain to Breakeven | 907.1% | 3.9% |
| Time to Breakeven | 981 days | 6 days |
In The Past
Tandem Diabetes Care's stock fell -20.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 25.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | TNDM | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -20.5% | -7.8% |
| % Gain to Breakeven | 25.8% | 8.5% |
| Time to Breakeven | 15 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -57.4% | -9.5% |
| % Gain to Breakeven | 134.5% | 10.5% |
| Time to Breakeven | 137 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -42.5% | -6.7% |
| % Gain to Breakeven | 74.0% | 7.1% |
| Time to Breakeven | 302 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -47.4% | -33.7% |
| % Gain to Breakeven | 90.1% | 50.9% |
| Time to Breakeven | 54 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -20.6% | -19.2% |
| % Gain to Breakeven | 25.9% | 23.8% |
| Time to Breakeven | 9 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -90.1% | -3.7% |
| % Gain to Breakeven | 907.1% | 3.9% |
| Time to Breakeven | 981 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -46.1% | -12.2% |
| % Gain to Breakeven | 85.4% | 13.9% |
| Time to Breakeven | 2034 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -50.5% | -6.8% |
| % Gain to Breakeven | 101.9% | 7.3% |
| Time to Breakeven | 2108 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -44.3% | -17.9% |
| % Gain to Breakeven | 79.5% | 21.8% |
| Time to Breakeven | 784 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -39.7% | -15.4% |
| % Gain to Breakeven | 65.7% | 18.2% |
| Time to Breakeven | 197 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -34.1% | -53.4% |
| % Gain to Breakeven | 51.6% | 114.4% |
| Time to Breakeven | 82 days | 1085 days |
In The Past
Tandem Diabetes Care's stock fell -20.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 25.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Tandem Diabetes Care (TNDM)
Tandem Diabetes Care (TNDM) is a medical device company dedicated to designing, developing, and commercializing advanced products for individuals living with insulin-dependent diabetes. The company focuses on improving diabetes management through innovative technology, providing solutions that assist users in administering insulin and tracking critical health data.
The core of Tandem's product offering is the t:slim X2 insulin delivery system, a sophisticated pump platform that includes the t:slim X2 pump, disposable insulin cartridges, and infusion sets. This system often incorporates intelligent technologies such as Basal-IQ and Control-IQ, which integrate with continuous glucose monitoring (CGM) devices to automate insulin delivery. Complementing the pump, Tandem also provides the Tandem Device Updater for software updates, t:connect—a web-based data management application that consolidates therapy data from pumps, CGMs, and blood glucose meters, and the Sugarmate mobile app, offering comprehensive support for diabetes management. The company also maintains strategic development and commercialization agreements with key partners like Dexcom and Abbott Laboratories.
Tandem Diabetes Care's primary customers are people with insulin-dependent diabetes, their caregivers, and their healthcare providers. The company serves these markets both within the United States and internationally, aiming to deliver integrated solutions that simplify and enhance the daily management of diabetes.
AI Analysis | Feedback
The Apple of insulin pumps
Like Dexcom or Abbott, but providing automated insulin delivery systems instead of glucose monitoring
The Tesla of automated insulin delivery
AI Analysis | Feedback
- t:slim X2 insulin delivery system: A flagship insulin pump platform that includes the pump, disposable insulin cartridge, and infusion set for people with insulin-dependent diabetes.
- t:slim X2 insulin with Basal-IQ and Control-IQ technology: Enhanced versions of the t:slim X2 pump featuring predictive low-glucose suspend and advanced hybrid closed-loop insulin delivery.
- t:slim X2 with G5 Integration: A version of the t:slim X2 insulin pump designed for integration with the Dexcom G5 continuous glucose monitoring system.
- Tandem Device Updater: A software tool that enables users to update the software of their Tandem insulin pump.
- t:connect: A web-based data management application that visually displays diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters.
- Sugarmate: A mobile application designed for people with diabetes who use insulin.
AI Analysis | Feedback
Tandem Diabetes Care (TNDM) primarily sells its products to individuals. The major categories of customers it serves are:
- Individuals with insulin-dependent diabetes: These are the primary end-users of Tandem's core products, such as the t:slim X2 insulin delivery system, pumps, and associated technologies like Basal-IQ and Control-IQ.
- Caregivers of individuals with insulin-dependent diabetes: This category includes parents, guardians, or family members who manage or monitor the diabetes care of a user, often utilizing tools like the t:connect web-based data management application and the Sugarmate mobile app.
- Healthcare Providers: While not direct purchasers of the devices for their own use, healthcare professionals (e.g., endocrinologists, diabetes educators) are crucial customers as they prescribe, recommend, and manage therapy for individuals using Tandem's products. They also utilize the t:connect application to review patient data and optimize treatment plans.
AI Analysis | Feedback
- Dexcom, Inc. (DXCM)
- Abbott Laboratories (ABT)
AI Analysis | Feedback
John Sheridan, President and Chief Executive Officer
John Sheridan has served as President and Chief Executive Officer of Tandem Diabetes Care since March 2019 and as a member of its Board of Directors since June 2019. Previously, he was Executive Vice President and Chief Operating Officer from April 2013. His prior experience includes serving as Chief Operating Officer of Rapiscan Systems, Inc., Executive Vice President of Research and Development and Operations for Volcano Corporation, Executive Vice President of Operations at CardioNet, Inc. (now BioTelemetry, Inc.), and Vice President of Operations at Digirad Corporation. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an M.B.A. from Boston University.
Leigh Vosseller, Executive Vice President and Chief Financial Officer
Leigh Vosseller was promoted to Executive Vice President and Chief Financial Officer of Tandem Diabetes Care, effective January 1, 2018, having joined the company in September 2013 as Vice President of Finance. Before joining Tandem, Ms. Vosseller served as Vice President and CFO at Genoptix Inc. (a Novartis company) starting in 2011, after initially joining that company in 2008. Prior to that, she held a senior finance position at Biosite Incorporated, where she contributed to developing the financial and administrative infrastructure for international expansion. Biosite Incorporated was later acquired by Inverness Medical Innovations. Ms. Vosseller is a Certified Public Accountant (inactive) and holds a bachelor's degree in accounting from Missouri State University.
Rick Carpenter, Chief Technical Officer
Rick Carpenter has served as Tandem Diabetes Care's Chief Technical Officer since November 2021. With over 30 years of engineering technology leadership experience, he previously served as the Senior Vice President of Engineering at Inseego Corporation from February 2020, where he led the worldwide engineering team.
Elizabeth Gasser, Executive Vice President and Chief Strategy and Product Officer
Elizabeth Gasser has served as Executive Vice President and Chief Strategy and Product Officer since November 2023. She was Executive Vice President and Chief Strategy Officer from June 2021 to November 2023, and Executive Vice President, Strategy and Corporate Development from January 2020 to June 2021. In her role, Ms. Gasser is responsible for the company's strategy, corporate development, product management, behavioral sciences, and competitive intelligence functions. She holds a B.A. and an M.A. in Economics from the University of Cambridge.
Shannon Hansen, Executive Vice President, Chief Legal, Privacy and Compliance Officer and Secretary
Shannon Hansen has served as Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary since April 2024, and as Chief Legal, Privacy & Compliance Officer and Secretary since August 2023. She joined Tandem Diabetes Care in January 2022 as Senior Vice President, General Counsel, Chief Compliance Officer and Secretary, overseeing the company's legal, compliance, and privacy functions.
AI Analysis | Feedback
The key risks to Tandem Diabetes Care (TNDM) include:
Intense Market Competition
Tandem Diabetes Care operates in a highly competitive insulin pump market, facing pressure from established players like Insulet (Omnipod) and Medtronic, as well as new entrants. This competitive landscape has led to market share erosion for Tandem in the U.S. and can impact product pricing and reimbursement. The company's ability to differentiate its products and maintain strong relationships with healthcare providers and patients is crucial to navigate this environment.Product Reliability, Regulatory Hurdles, and Recalls
As a medical device company, Tandem Diabetes Care is subject to a stringent and evolving regulatory environment, particularly concerning FDA approvals. The company has experienced significant product reliability issues, including a Class I recall for its Tandem Mobi insulin pump due to a software malfunction that could interfere with insulin delivery and cause hyperglycemia. Additionally, a medical device correction was issued for certain t:slim X2 insulin pumps due to a wiring issue that could cause them to malfunction and stop delivering insulin, linked to 700 adverse events and 59 injuries. Such incidents underscore the continuous operational necessity of maintaining compliance, ensuring product reliability, and the potential impact on patient trust and brand reputation.Impact of Technological Disruption and Alternative Therapies
The diabetes technology landscape is constantly evolving, presenting a risk of technological disruption where rapid advancements or the emergence of alternative treatment modalities could render Tandem's current offerings obsolete or reduce demand for insulin pumps. Specifically, the uptake of GLP-1 drugs is identified as a competitive pressure that could shift clinical approaches to diabetes management. Furthermore, the company faces an ongoing challenge in achieving sustained profitability, having incurred significant operating losses, which could limit its ability to fund ongoing operations and invest in critical research and development to stay ahead of these technological shifts.AI Analysis | Feedback
The clear emerging threat for Tandem Diabetes Care is **Insulet's Omnipod 5 Automated Insulin Delivery (AID) System.**
Insulet's Omnipod 5, which integrates with continuous glucose monitors (CGMs) like Dexcom G6, represents a significant challenge to Tandem's t:slim X2 system. While both offer automated insulin delivery, Omnipod 5's key differentiator is its **tubeless patch pump design**. This form factor provides users with greater freedom, discretion, and a reduced burden compared to Tandem's tubed pump system. As Omnipod 5 gains market share and adoption, particularly among new pump users and those seeking alternatives to traditional tubed pumps, it directly threatens Tandem's core product by offering a fundamentally different and often preferred user experience within the same automated insulin delivery market.
AI Analysis | Feedback
Tandem Diabetes Care, Inc. (TNDM) operates primarily in the insulin pump market, a key segment of the broader diabetes device market, addressing the needs of individuals with insulin-dependent diabetes, including both Type 1 and a growing segment of Type 2 diabetes patients.
Addressable Markets:
- Global Insulin Pump Market: The global insulin pump market was valued at approximately USD 7.05 billion in 2025 and is projected to reach USD 22.45 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 13.41% during the forecast period (2026-2034). Another estimate places the global insulin pump market at USD 6.05 billion in 2024, poised to grow to USD 12.32 billion by 2033 with a CAGR of 8.22% from 2026–2033.
- U.S. Insulin Pump Market: In the United States, the insulin pump market was valued at approximately USD 2.69 billion in 2025 and is expected to reach USD 3.73 billion by 2034, growing at a CAGR of 3.67% from 2026-2034. The U.S. accounted for approximately 40.8% of the global insulin pump market in 2024.
- Global Type 1 Diabetes Market: This market, which encompasses treatments and devices for Type 1 diabetes, was estimated to be valued at USD 16.97 billion in 2025 and is expected to reach USD 26.22 billion by 2032, with a CAGR of 6.4% from 2025 to 2032. Another report estimates the global Type 1 diabetes market size at USD 37.60 billion in 2025, predicted to increase to approximately USD 79.14 billion by 2035.
- Expanded Addressable Market for Type 2 Diabetes (U.S. and Global): Tandem Diabetes Care has significantly expanded its addressable market to include adults with Type 2 diabetes who require insulin, a strategic move reinforced by the FDA clearance of its Control-IQ+ technology for this population in late 2024. This expansion has "effectively more than doubled the company's addressable market". Tandem aims to increase its market share in the Type 2 diabetes segment from a current 5-10% to 20-25% during 2025. There are more than 2 million insulin-dependent Type 2 diabetes patients in the U.S., representing a potential for tens of thousands of additional insulin pump sales.
- Global Diabetes Device Market (Broader Market): The overall global diabetes device market is projected to grow significantly from an estimated USD 45.1 billion in 2024 to USD 118.6 billion by 2032, at a CAGR of 11.4%.
AI Analysis | Feedback
Here are the expected drivers of future revenue growth for Tandem Diabetes Care (TNDM) over the next 2-3 years:
Drivers of Future Revenue Growth for Tandem Diabetes Care (TNDM)
- New Product Launches and Integrations: The commercialization and scaling of new products, particularly the Tandem Mobi insulin delivery system, is a significant growth driver. The Mobi system is anticipated to be a key driver of long-term margin improvement. Additionally, the ongoing integration of Tandem's pumps, like the t:slim X2 and Mobi, with advanced continuous glucose monitoring (CGM) sensors such as Dexcom G7 and Abbott FreeStyle Libre 2 Plus/3 Plus, is expected to enhance product adoption and expand the market for their automated insulin delivery (AID) systems.
- International Expansion and Direct Sales Model: Tandem Diabetes Care is actively expanding its international presence by transitioning to direct operations in key European markets, including the UK, Switzerland, and Austria, starting in early 2026. This strategic shift is designed to strengthen the company's financial position by accelerating sales growth and driving margin expansion. International sales have demonstrated robust growth, with a 35% year-over-year increase in Q1 2025.
- Growth in Customer Base and Renewals: The company anticipates continued revenue growth from its expanding installed base of customers worldwide. Strong customer retention and a high capture rate from warranty expirations are contributing to double-digit year-over-year growth in recurring supply and renewal revenue streams.
- Expansion into the Type 2 Diabetes Market: Tandem views the Type 2 diabetes population as a meaningful longer-term growth opportunity, with the potential to double its addressable market in the U.S.. The company is expanding the promotion of its Control-IQ+ technology for Type 2 diabetes following positive feedback from initial pilots.
- Pharmacy Channel Expansion and New Reimbursement Models: Tandem is focused on advancing a multichannel reimbursement strategy, including expanding access through the pharmacy channel. The shift to a "pay-as-you-go" pharmacy structure is expected to lower upfront costs for customers, enhance market share, and foster customer loyalty, thereby generating recurring revenue streams, despite potential near-term revenue recognition headwinds.
AI Analysis | Feedback
Share Repurchases
No significant share repurchase programs or dollar amounts spent on repurchases by Tandem Diabetes Care were prominently disclosed in the last 3-5 years.
Share Issuance
- In February 2026, Tandem Diabetes Care priced a private offering of $265 million in aggregate principal amount of 0.00% convertible senior notes due 2032.
- The offering was upsized from a previously announced $200 million, with an option granted to initial purchasers for an additional $35 million in notes.
- Net proceeds from this offering are estimated to be approximately $256.7 million, or about $290.7 million if the initial purchasers exercise their option in full, intended for general corporate purposes including potential acquisitions and capital expenditures.
Outbound Investments
- Tandem Diabetes has acquired four companies, including Advanced Microfluidics and Amf Medica.
- The company has also made one investment in CeQur.
Capital Expenditures
- Tandem Diabetes Care anticipates using a portion of the net proceeds from its February 2026 convertible senior notes offering for capital expenditure, among other general corporate purposes.
- The company's principal sources of cash historically have included product sales, equity offerings, and debt financing, which have been used to fund material cash requirements including capital expenditures.
- For the full year 2025, Tandem reported positive free cash flow of $3.1 million, which is defined as cash provided by operating activities less capital expenditures.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 89.84 |
| Mkt Cap | 67.9 |
| Rev LTM | 20,590 |
| Op Inc LTM | 3,930 |
| FCF LTM | 3,428 |
| FCF 3Y Avg | 1,298 |
| CFO LTM | 4,556 |
| CFO 3Y Avg | 4,118 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 12.3% |
| Rev Chg 3Y Avg | 13.4% |
| Rev Chg Q | 12.5% |
| QoQ Delta Rev Chg LTM | 2.9% |
| Op Inc Chg LTM | 56.1% |
| Op Inc Chg 3Y Avg | 32.6% |
| Op Mgn LTM | 18.1% |
| Op Mgn 3Y Avg | 17.3% |
| QoQ Delta Op Mgn LTM | 0.9% |
| CFO/Rev LTM | 21.2% |
| CFO/Rev 3Y Avg | 19.6% |
| FCF/Rev LTM | 14.6% |
| FCF/Rev 3Y Avg | 13.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 67.9 |
| P/S | 3.8 |
| P/Op Inc | 22.0 |
| P/EBIT | 21.2 |
| P/E | 28.5 |
| P/CFO | 18.0 |
| Total Yield | 3.0% |
| Dividend Yield | 0.3% |
| FCF Yield 3Y Avg | 2.4% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 4.4% |
| 3M Rtn | -3.7% |
| 6M Rtn | -19.6% |
| 12M Rtn | -8.2% |
| 3Y Rtn | -20.5% |
| 1M Excs Rtn | 5.5% |
| 3M Excs Rtn | -17.3% |
| 6M Excs Rtn | -26.0% |
| 12M Excs Rtn | -29.5% |
| 3Y Excs Rtn | -93.2% |
Comparison Analyses
Price Behavior
Price Behavior
| Market Price | $15.43 | |
| Market Cap ($ Bil) | 1.1 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -45.4% | |
| 50 Days | 200 Days | |
| DMA Price | $16.52 | $18.69 |
| DMA Trend | up | down |
| Distance from DMA | -6.6% | -17.4% |
| 3M | 1YR | |
| Volatility | 81.8% | 79.8% |
| Downside Capture | 219.88 | 179.35 |
| Upside Capture | 58.17 | 132.30 |
| Correlation (SPY) | 22.2% | 20.3% |
TNDM Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.91 | 0.54 | 1.09 | 1.28 | 1.28 | 1.27 |
| Up Beta | -2.97 | -2.94 | 0.10 | 0.23 | 0.31 | 1.00 |
| Down Beta | 0.83 | 2.73 | 2.35 | 1.82 | 1.32 | 1.13 |
| Up Capture | 132% | -32% | 25% | 80% | 142% | 197% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 8 | 18 | 27 | 52 | 117 | 354 |
| Down Capture | 232% | 155% | 221% | 171% | 152% | 111% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 13 | 23 | 36 | 73 | 135 | 393 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TNDM | |
|---|---|---|---|---|
| TNDM | -8.1% | 79.7% | 0.23 | - |
| Sector ETF (XLV) | 23.0% | 15.7% | 1.13 | 32.4% |
| Equity (SPY) | 20.7% | 12.5% | 1.22 | 20.3% |
| Gold (GLD) | 23.0% | 27.8% | 0.73 | 11.7% |
| Commodities (DBC) | 22.9% | 18.6% | 0.97 | -4.8% |
| Real Estate (VNQ) | 13.6% | 13.8% | 0.68 | 24.5% |
| Bitcoin (BTCUSD) | -41.8% | 42.8% | -1.14 | 2.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TNDM | |
|---|---|---|---|---|
| TNDM | -31.1% | 67.9% | -0.26 | - |
| Sector ETF (XLV) | 7.1% | 14.9% | 0.29 | 32.2% |
| Equity (SPY) | 13.3% | 17.1% | 0.60 | 34.3% |
| Gold (GLD) | 17.8% | 18.3% | 0.79 | 9.3% |
| Commodities (DBC) | 7.6% | 19.5% | 0.29 | 2.2% |
| Real Estate (VNQ) | 3.1% | 18.9% | 0.06 | 30.5% |
| Bitcoin (BTCUSD) | 13.2% | 53.5% | 0.43 | 15.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TNDM | |
|---|---|---|---|---|
| TNDM | -14.4% | 77.8% | 0.17 | - |
| Sector ETF (XLV) | 10.9% | 16.6% | 0.54 | 28.0% |
| Equity (SPY) | 15.7% | 17.9% | 0.75 | 28.6% |
| Gold (GLD) | 11.6% | 16.1% | 0.59 | 4.9% |
| Commodities (DBC) | 6.2% | 18.0% | 0.27 | 7.1% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 21.9% |
| Bitcoin (BTCUSD) | 57.9% | 66.2% | 0.98 | 8.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/10/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | -16.2% | -23.4% | 0.0% |
| 2/19/2026 | 32.7% | 39.3% | 34.0% |
| 11/6/2025 | 22.0% | 31.5% | 53.3% |
| 8/6/2025 | -19.9% | -22.7% | -12.6% |
| 4/30/2025 | 18.6% | 32.1% | 17.6% |
| 2/26/2025 | -35.2% | -43.1% | -41.0% |
| 11/6/2024 | -2.7% | -13.3% | -12.1% |
| 8/1/2024 | 18.3% | 4.7% | 23.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 6 | 9 |
| # Negative | 10 | 11 | 8 |
| Median Positive | 18.6% | 26.0% | 23.5% |
| Median Negative | -15.0% | -19.6% | -24.8% |
| Max Positive | 32.7% | 39.3% | 53.3% |
| Max Negative | -35.2% | -43.1% | -41.0% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | -16.2% | -23.4% | 0.0% |
| 2/19/2026 | 32.7% | 39.3% | 34.0% |
| 11/6/2025 | 22.0% | 31.5% | 53.3% |
| 8/6/2025 | -19.9% | -22.7% | -12.6% |
| 4/30/2025 | 18.6% | 32.1% | 17.6% |
| 2/26/2025 | -35.2% | -43.1% | -41.0% |
| 11/6/2024 | -2.7% | -13.3% | -12.1% |
| 8/1/2024 | 18.3% | 4.7% | 23.5% |
| 5/2/2024 | 22.3% | 20.5% | 42.2% |
| 2/21/2024 | 10.9% | 17.9% | 41.3% |
| 11/1/2023 | -14.4% | -12.6% | 19.4% |
| 8/3/2023 | 4.4% | -8.4% | -12.9% |
| 5/3/2023 | -6.1% | -16.6% | -38.0% |
| 2/22/2023 | -4.7% | -8.3% | 4.2% |
| 11/2/2022 | -28.4% | -29.9% | -16.7% |
| 8/3/2022 | -15.0% | -19.6% | -35.3% |
| 5/4/2022 | -15.0% | -26.2% | -32.8% |
| SUMMARY STATS | |||
| # Positive | 7 | 6 | 9 |
| # Negative | 10 | 11 | 8 |
| Median Positive | 18.6% | 26.0% | 23.5% |
| Median Negative | -15.0% | -19.6% | -24.8% |
| Max Positive | 32.7% | 39.3% | 53.3% |
| Max Negative | -35.2% | -43.1% | -41.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/19/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 04/30/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/21/2024 | 10-K |
| 09/30/2023 | 11/01/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/22/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/19/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 04/30/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/21/2024 | 10-K |
| 09/30/2023 | 11/01/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/22/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
| 03/31/2022 | 05/04/2022 | 10-Q |
| 12/31/2021 | 02/22/2022 | 10-K |
| 09/30/2021 | 11/03/2021 | 10-Q |
| 06/30/2021 | 08/04/2021 | 10-Q |
| 03/31/2021 | 05/05/2021 | 10-Q |
| 12/31/2020 | 02/24/2021 | 10-K |
| 09/30/2020 | 11/05/2020 | 10-Q |
| 06/30/2020 | 07/30/2020 | 10-Q |
| 03/31/2020 | 04/30/2020 | 10-Q |
| 12/31/2019 | 02/24/2020 | 10-K |
| 09/30/2019 | 11/04/2019 | 10-Q |
| 06/30/2019 | 08/01/2019 | 10-Q |
Recent Forward Guidance
Updated 7/1/2026Latest: Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 1.06 Bil | 1.07 Bil | 1.08 Bil | 0 | Affirmed | Guidance: 1.07 Bil for 2026 | |
| 2026 United States Sales | 730.00 Mil | 737.50 Mil | 745.00 Mil | 0 | Affirmed | Guidance: 737.50 Mil for 2026 | |
| 2026 International Sales | 335.00 Mil | 337.50 Mil | 340.00 Mil | 0 | Affirmed | Guidance: 337.50 Mil for 2026 | |
| 2026 Gross Margin | 56.0% | 56.5% | 57.0% | 0 | 0 | Affirmed | Guidance: 56.5% for 2026 |
| 2026 Adjusted EBITDA Margin | 5.0% | 5.5% | 6.0% | 0 | 0 | Affirmed | Guidance: 5.5% for 2026 |
Prior: Q4 2025 Earnings Reported 2/19/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 1.06 Bil | 1.07 Bil | 1.08 Bil | 7.5% | Raised | Guidance: 1.00 Bil for 2025 | |
| 2026 United States Sales | 730.00 Mil | 737.50 Mil | 745.00 Mil | 5.4% | Raised | Guidance: 700.00 Mil for 2025 | |
| 2026 International Sales | 335.00 Mil | 337.50 Mil | 340.00 Mil | 12.5% | Raised | Guidance: 300.00 Mil for 2025 | |
| 2026 Gross Margin | 56.0% | 56.5% | 57.0% | 5.6% | 3.0% | Raised | Guidance: 53.5% for 2025 |
| 2026 Adjusted EBITDA Margin | 5.0% | 5.5% | 6.0% | 10.5% | Raised | Guidance: -5.0% for 2025 | |
Q3 2025 Earnings Reported 11/6/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | 1.00 Bil | 0 | Affirmed | Guidance: 1.00 Bil for 2025 | |||
| 2025 U.S. Sales | 700.00 Mil | 0 | Affirmed | Guidance: 700.00 Mil for 2025 | |||
| 2025 International Sales | 300.00 Mil | 0 | Affirmed | Guidance: 300.00 Mil for 2025 | |||
| 2025 Gross Margin | 53.0% | 53.5% | 54.0% | 0 | 0 | Affirmed | Guidance: 53.5% for 2025 |
| 2025 Adjusted EBITDA Margin | -5.0% | 0 | 0 | Affirmed | Guidance: -5.0% for 2025 | ||
| 2025 Non-cash charges | 115.00 Mil | 0 | Affirmed | Guidance: 115.00 Mil for 2025 | |||
Insider Activity
Updated 6/3/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Novara, Mark David | EVP & CHIEF COMMERCIAL OFFICER | Direct | Sell | 3182026 | 23.05 | 187 | 4,310 | 867,971 | Form |
| 2 | Novara, Mark David | EVP & CHIEF COMMERCIAL OFFICER | Direct | Sell | 3092026 | 22.81 | 2 | 46 | 820,453 | Form |
| 3 | Sheridan, John F | PRESIDENT & CEO | Direct | Buy | 8112025 | 10.23 | 10,000 | 102,318 | 1,087,917 | Form |
| 4 | Vosseller, Leigh | EVP & CHIEF FINANCIAL OFFICER | Leigh A. Vosseller Trust | Buy | 8112025 | 10.89 | 13,720 | 149,404 | 278,553 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Novara, Mark David | EVP & CHIEF COMMERCIAL OFFICER | Direct | Sell | 3182026 | 23.05 | 187 | 4,310 | 867,971 | Form |
| 2 | Novara, Mark David | EVP & CHIEF COMMERCIAL OFFICER | Direct | Sell | 3092026 | 22.81 | 2 | 46 | 820,453 | Form |
| 3 | Sheridan, John F | PRESIDENT & CEO | Direct | Buy | 8112025 | 10.23 | 10,000 | 102,318 | 1,087,917 | Form |
| 4 | Vosseller, Leigh | EVP & CHIEF FINANCIAL OFFICER | Leigh A. Vosseller Trust | Buy | 8112025 | 10.89 | 13,720 | 149,404 | 278,553 | Form |
Tandem Diabetes Care — Investor Video Playlist
Products & Services
How to Pair the Tandem t:slim Mobile App with the Abbott FreeStyle Libre 3 Plus Sensor
Products & Services
Moments That Matter | Because of Tandem
Products & Services
Episode 5: Team Tandem + Juicebox Podcast for Kids
Products & Services
Embracing Pump Therapy: Taylor’s Transition from MDI to the Tandem Mobi System
Products & Services
How to Pair the Tandem t:slim Mobile App with Your t:slim X2 Pump
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/7/2026